Panalitian Klinik Cleveland Anyar nunjukkeun pikeun kahiji kalina yén ibrutinib (ibrutinib) anu disatujuan FDA pikeun limfoma sareng leukemia ogé tiasa ngabantosan ngubaran tumor otak anu paling umum sareng maot, sareng tiasa waé hiji dinten dianggo pikeun penderita glioblastoma Sareng ningkatkeun tingkat kasalametan.
Numutkeun laporan Asosiasi Tumor Otak Amérika, tingkat kasalametan glioblastoma rendah pisan, sareng kasalametan median pasien anu nampi perawatan standar kirang ti 15 bulan. Glioblastoma mangrupikeun tumor otak primér anu paling maot sareng tahan pisan kana pangobatan ayeuna. Aya kabutuhan urgent pikeun nyayogikeun pasien ieu kalayan pangobatan énggal pas mungkin.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain tumor in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
